Age‐Associated Memory Impairment and Alzheimer's Disease

Blass, John P.

doi:10.1111/j.1532-5415.1996.tb02443.x

Cited by 9 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Costs for 1 year of care in a nursing home vary from $35,000 51 to $47,000 52 61 and an accompanying editorial suggested that these patients may be identibecause the occurrence of this disease may be treated as a random event due to the limited information fied with the combination of a neuropsychologic test and a simple genetic test. 62 If individuals with early available to all parties.…”

Section: Future Use Of Genetic Information By Insurersmentioning

confidence: 99%

Insurance underwriting in the genetic era

Pokorski¹

1997

Cancer

View full text Add to dashboard Cite

corresponding recognition that most medical information, screening and diagnostic tests, and disease processes have a genetic component. However, these scientific Cologne Life Reinsurance Company, Stamford, Connecticut.advances have been accompanied by fears that insurers might misuse genetic information to the detriment of the general public.METHODS. This article addresses the principal issues regarding insurers' use of genetic information from the perspective of the insurance industry. Alzheimer's disease is used to exemplify problems that would occur if insurers did not consider genetic information that was known to applicants. RESULTS.Prohibiting use of genetic information would make it difficult to sell individually underwritten coverage at an affordable premium because insurers could not use most of the risk parameters that correlate with likelihood of claim.CONCLUSIONS. It appears that the use of genetic factors in risk classification will eventually become accepted practice. Insurers and the medical community must be proactive in seeking solutions to difficulties that can be envisioned in the future. Iwould like to thank the American Cancer Society for providing an opportunity for me to meet with other physicians who share my desire to ensure that insurance protection remains widely available and highly affordable in the genetic era that lies ahead. To the best of my knowledge, this is the world's first cancer genetics conference with an agenda that seeks to identify and solve proactively insurance difficulties that can be envisioned ahead of time. I understand that consumers and most physicians know very little about the inner workings of the private insurance mechanism, and people wonder if obtaining coverage will become more difficult in the future. For this reason, I will confine my remarks to my most deeply held convictions as a consumer, physician, and insurance professional regarding what will probably occur and, in fact, what must occur if individually underwritten insurance is to remain a product that appeals to most people. In this regard, I must emphasize that I appear today in a personal capacity and that the opinions expressed in this paper, whether explicit or implied, are mine alone and not necessarily those of the organizations with which I am associated.Presented at the American Cancer Society Workshop on Heritable Cancer Syndromes and Focus of the DiscussionGenetic Testing, Chicago, Illinois, October 7-8, 1996. Insurance figures prominently in articles that discuss concerns engendered by advances in genetic technology. Two of the more detailed from the perspective of an insurance medical director. The goal is to foster an atmosphere of understanding and mutual respect and point

show abstract

Section: Future Use Of Genetic Information By Insurersmentioning

confidence: 99%

Insurance underwriting in the genetic era

Pokorski¹

1997

Cancer

View full text Add to dashboard Cite

show abstract

“…Finally, whereas the inclusion criteria appear to be overinclusive, the exclusion criteria have been criticised for being over‐restrictive because of multimorbidity in older age which does not affect memory performance (18). Thus, the construct is unlikely to identify homogenous samples and is too broad a clinical entity to be useful (16, 17, 20–24).…”

Section: Age‐associated Memory Impairment and Its Modificationsmentioning

confidence: 99%

Mild cognitive impairment¹– a review of prevalence, incidence and outcome according to current approaches

Bischkopf

Busse

Angermeyer

2002

Acta Psychiatr Scand

219

163

View full text Add to dashboard Cite

show abstract

“…Ambulatórios multidisciplinares especializados para o atendimento desses pacientes podem ser encontrados em ambientes universitários [1][2][3][4] . Distúrbios cognitivos e comportamentais podem ocorrer como parte do enve-lhecimento fisiológico, como sintomas de diversas doenças neurológicas e sistêmicas ou como sintomas de síndromes demenciais [5][6][7] . Perdas cognitivas e demências são transtornos neurológicos freqüentes na senescência.…”

Section: Cognitive Disorders and Dementias In The Private Practice Ofunclassified

Transtornos cognitivos e demências na clínica privada do especialista: estudo piloto de um inquérito de auto-avaliação

Vale

2004

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

Age‐Associated Memory Impairment and Alzheimer's Disease

Cited by 9 publications

References 21 publications

Insurance underwriting in the genetic era

Insurance underwriting in the genetic era

Mild cognitive impairment¹– a review of prevalence, incidence and outcome according to current approaches

Transtornos cognitivos e demências na clínica privada do especialista: estudo piloto de um inquérito de auto-avaliação

Contact Info

Product

Resources

About

Age‐Associated Memory Impairment and Alzheimer's Disease

Cited by 9 publications

References 21 publications

Insurance underwriting in the genetic era

Insurance underwriting in the genetic era

Mild cognitive impairment1– a review of prevalence, incidence and outcome according to current approaches

Transtornos cognitivos e demências na clínica privada do especialista: estudo piloto de um inquérito de auto-avaliação

Contact Info

Product

Resources

About

Mild cognitive impairment¹– a review of prevalence, incidence and outcome according to current approaches